The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Chronic viral coinfections differentially affect the likelihood of developing long COVID
Open accessAbstract
BACKGROUNDThe presence and reactivation of chronic viral infections, such as EBV, CMV, and HIV, have been proposed as potential contributors to long COVID (LC), but studies in well-characterized postacute cohorts of individuals with COVID-19 over a longer time course consistent with current case definitions of LC are limited.METHODSIn a cohort of 280 adults with prior SARS-CoV-2 infection, we assessed the presence and types of LC symptoms and prior medical history (including COVID-19 history and HIV status) and performed serological testing for EBV and CMV using a commercial laboratory. We used covariate-adjusted binary logistic regression models to identify independent associations between variables and LC symptoms.RESULTSWe observed that LC symptoms, such as fatigue and neurocognitive dysfunction, at a median of 4 months following initial diagnosis were independently associated with serological evidence suggesting recent EBV reactivation (early antigen-diffuse IgG positivity) or high nuclear antigen (EBNA) IgG levels but not with ongoing EBV viremia. Serological evidence suggesting recent EBV reactivation (early antigen-diffuse IgG positivity) was most strongly associated with fatigue (OR = 2.12). Underlying HIV infection was also independently associated with neurocognitive LC (OR = 2.5). Interestingly, participants who had serologic evidence of prior CMV infection were less likely to develop neurocognitive LC (OR = 0.52).CONCLUSIONOverall, these findings suggest differential effects of chronic viral coinfections on the likelihood of developing LC and association with distinct syndromic patterns. Further assessment during the acute phase of COVID-19 is warranted.TRIAL REGISTRATIONLong-term Impact of Infection with Novel Coronavirus; ClinicalTrials.gov NCT04362150.FUNDINGThis work was supported by NIH/National Institute of Allergy and Infectious Diseases grants (3R01AI141003-03S1, R01AI158013, and K24AI145806); the Zuckerberg San Francisco General Hospital Department of Medicine and Division of HIV, Infectious Diseases, and Global Medicine; and the UCSF-Bay Area Center for AIDS Research (P30-AI027763).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Cook, J. R., Nordvig, A. S., Shalev, D., Sehrawat, T. S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01283-z · Cited by 4,862
The PHQ-15: Validity of a New Measure for Evaluating the Severity of Somatic Symptoms
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200203000-00008 · Cited by 3,298
Bjornevik, K., Cortese, M., Healy, B. C., Kuhle, J., Mina, M. J., Leng, Y., Elledge, S. J., Niebuhr, D. W., Scher, A. I., Munger, K. L., et al. (2022) · Science · doi:10.1126/science.abj8222 · Cited by 2,049
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Multiple early factors anticipate post-acute COVID-19 sequelae
Su, Y., Yuan, D., Chen, D. G., Ng, R. H., Wang, K., Choi, J., Li, S., Hong, S., Zhang, R., Xie, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.014 · Cited by 1,156 · cited 5×
“We and others have previously demonstrated that markers of persistent immune activation and inflammation are elevated in the setting of LC (3, 4, 7, 39, 46).”
InfluentialSelf-citationPhetsouphanh, C., Darley, D. R., Wilson, D. B., Howe, A., Munier, C. M. L., Patel, S. K., Juno, J. A., Burrell, L. M., Kent, S. J., Dore, G. J., et al. (2022) · Nature Immunology · doi:10.1038/s41590-021-01113-x · Cited by 1,015
Seroprevalence of Cytomegalovirus Infection in the United States, 1988-1994
Staras, S. A. S., Dollard, S. C., Radford, K. W., Flanders, W. D., Pass, R. F., & Cannon, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/508173 · Cited by 1,007
SARS-CoV-2 infection and persistence in the human body and brain at autopsy
Stein, S. R., Ramelli, S. C., Grazioli, A., Chung, J.-Y., Singh, M., Yinda, C. K., Winkler, C. W., Sun, J., Dickey, J. M., Ylaya, K., et al. (2022) · Nature · doi:10.1038/s41586-022-05542-y · Cited by 991
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM
Lanz, T. V., Brewer, R. C., Ho, P. P., Moon, J.-S., Jude, K. M., Fernandez, D., Fernandes, R. A., Gomez, A. M., Nadj, G.-S., Bartley, C. M., et al. (2022) · Nature · doi:10.1038/s41586-022-04432-7 · Cited by 908
Distinguishing features of long COVID identified through immune profiling
Klein, J., Wood, J., Jaycox, J. R., Dhodapkar, R. M., Lu, P., Gehlhausen, J. R., Tabachnikova, A., Greene, K., Tabacof, L., Malik, A. A., et al. (2023) · Nature · doi:10.1038/s41586-023-06651-y · Cited by 806
Epstein-Barr virus: Biology and clinical disease
Damania, B., Kenney, S. C., & Raab-Traub, N. (2022) · Cell · doi:10.1016/j.cell.2022.08.026 · Cited by 612
Seeßle, J., Waterboer, T., Hippchen, T., Simon, J., Kirchner, M., Lim, A., Müller, B., & Merle, U. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab611 · Cited by 540
Primary Epstein-Barr virus infection
Dunmire, S. K., Verghese, P. S., & Balfour, H. H. (2018) · Journal of Clinical Virology · doi:10.1016/j.jcv.2018.03.001 · Cited by 520
Pretorius, E., Vlok, M., Venter, C., Bezuidenhout, J. A., Laubscher, G. J., Steenkamp, J., & Kell, D. B. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01359-7 · Cited by 518
Natarajan, A., Zlitni, S., Brooks, E. F., Vance, S. E., Dahlen, A., Hedlin, H., Park, R. M., Han, A., Schmidtke, D. T., Verma, R., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.001 · Cited by 415
Wikby, A. (2002) · Experimental Gerontology · doi:10.1016/s0531-5565(01)00212-1 · Cited by 414
Epstein-Barr Virus and Systemic Autoimmune Diseases
Houen, G., & Trier, N. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587380 · Cited by 379
Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation
Gold, J. E., Okyay, R. A., Licht, W. E., & Hurley, D. J. (2021) · Pathogens · doi:10.3390/pathogens10060763 · Cited by 371
Cytomegalovirus infection enhances the immune response to influenza
Furman, D., Jojic, V., Sharma, S., Shen-Orr, S. S., L. Angel, C. J., Onengut-Gumuscu, S., Kidd, B. A., Maecker, H. T., Concannon, P., Dekker, C. L., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2293 · Cited by 332
Peluso, M. J., Lu, S., Tang, A. F., Durstenfeld, M. S., Ho, H.-E., Goldberg, S. A., Forman, C. A., Munter, S. E., Hoh, R., Tai, V., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab490 · Cited by 320
Self-citationPostacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases
Zollner, A., Koch, R., Jukic, A., Pfister, A., Meyer, M., Rössler, A., Kimpel, J., Adolph, T. E., & Tilg, H. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.04.037 · Cited by 307
Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus
Poole, B. D., Scofield, R. H., Harley, J. B., & James, J. A. (2006) · Autoimmunity · doi:10.1080/08916930500484849 · Cited by 286
Wenzel, J., Lampe, J., Müller-Fielitz, H., Schuster, R., Zille, M., Müller, K., Krohn, M., Körbelin, J., Zhang, L., Özorhan, Ü., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00926-1 · Cited by 249
Peluso, M. J., Deitchman, A. N., Torres, L., Iyer, N. S., Munter, S. E., Nixon, C. C., Donatelli, J., Thanh, C., Takahashi, S., Hakim, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109518 · Cited by 248
Self-citationHess, R. D. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.8.3381-3387.2004 · Cited by 232
Shnayder, M., Nachshon, A., Krishna, B., Poole, E., Boshkov, A., Binyamin, A., Maza, I., Sinclair, J., Schwartz, M., & Stern-Ginossar, N. (2018) · mBio · doi:10.1128/mbio.00013-18 · Cited by 170
A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings
Sneller, M. C., Liang, C., Marques, A. R., Chung, J. Y., Shanbhag, S. M., Fontana, J. R., Raza, H., Okeke, O., Dewar, R. L., Higgins, B. P., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-4905 · Cited by 162
Positive Epstein-Barr Virus Detection in Corona Virus Disease 2019 (COVID-19) Patients
Chen, T., Song, J., Liu, H., Zheng, H., & Chen, C. (2020) · Scientific Reports · doi:10.1038/s41598-021-90351-y · Cited by 161
Early clues regarding the pathogenesis of long-COVID
Peluso, M. J., & Deeks, S. G. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.02.008 · Cited by 147
Self-citationEvidence-Based Approach for Interpretation of Epstein-Barr Virus Serological Patterns
Klutts, J. S., Ford, B. A., Perez, N. R., & Gronowski, A. M. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00164-09 · Cited by 132
Peluso, M. J., Kelly, J. D., Lu, S., Goldberg, S. A., Davidson, M. C., Mathur, S., Durstenfeld, M. S., Spinelli, M. A., Hoh, R., Tai, V., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab640 · Cited by 131
Self-citationThe Epstein-Barr Virus EBNA1 Protein
Frappier, L. (2012) · Scientifica · doi:10.6064/2012/438204 · Cited by 125
EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count
Paolucci, S., Cassaniti, I., Novazzi, F., Fiorina, L., Piralla, A., Comolli, G., Bruno, R., Maserati, R., Gulminetti, R., Novati, S., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.12.051 · Cited by 119
Alcendor, D. J., Charest, A. M., Zhu, W. Q., Vigil, H. E., & Knobel, S. M. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-95 · Cited by 117
SARS-CoV-2 respiratory co-infections: Incidence of viral and bacterial co-pathogens
Singh, V., Upadhyay, P., Reddy, J. M., & Granger, J. K. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.087 · Cited by 108
Khoury, G., Fromentin, R., Solomon, A. E., Hartogensis, W., Killian, M. L., Hoh, R., Somsouk, M., Hunt, P. W., Girling, V., Sinclair, E., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix039 · Cited by 103
Self-citationBoglione, L., Meli, G., Poletti, F., Rostagno, R., Moglia, R., Cantone, M., Esposito, M., Scianguetta, C., Domenicale, B., Pasquale, F. D., et al. (2021) · QJM · doi:10.1093/qjmed/hcab297 · Cited by 95
Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID ‐19
Apple, A. C., Oddi, A., Peluso, M. J., Asken, B. M., Henrich, T. J., Kelly, J. D., Pleasure, S. J., Deeks, S. G., Allen, I. E., Martin, J. N., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51498 · Cited by 91
Self-citationPeluso, M. J., Sans, H. M., Forman, C. A., Nylander, A. N., Ho, H.-E., Lu, S., Goldberg, S. A., Hoh, R., Tai, V., Munter, S. E., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200003 · Cited by 90
Self-citationEpstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease
Middeldorp, J. M. (2015) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-22834-1_10 · Cited by 72
Peluso, M. J., Spinelli, M. A., Deveau, T., Forman, C. A., Munter, S. E., Mathur, S., Tang, A. F., Lu, S., Goldberg, S. A., Arreguin, M. I., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003338 · Cited by 67
Self-citationHuman Cytomegalovirus Interleukin 10 Homologs: Facing the Immune System
Poole, E. L., Neves, T. C., Oliveira, M. T., Sinclair, J. H., & da Silva, M. C. C. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00245 · Cited by 61
Health Status, Persistent Symptoms, and Effort Intolerance One Year After Acute COVID-19 Infection
Kingery, J. R., Safford, M. M., Martin, P., Lau, J. D., Rajan, M., Wehmeyer, G. T., Li, H. A., Alshak, M. N., Jabri, A., Kofman, A., et al. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07379-z · Cited by 59
Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies
Peluso, M. J., Anglin, K., Durstenfeld, M. S., Martin, J. N., Kelly, J. D., Hsue, P. Y., Henrich, T. J., & Deeks, S. G. (2022) · Pathogens and Immunity · doi:10.20411/pai.v7i1.518 · Cited by 58
Self-citationAlanio, C., Verma, A., Mathew, D., Gouma, S., Liang, G., Dunn, T. G., Oldridge, D. A., Weaver, J., Kuri-Cervantes, L., Pampena, M. B., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac020 · Cited by 53
CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients
Weber, S., Kehl, V., Erber, J., Wagner, K. I., Jetzlsperger, A.-M., Burrell, T., Schober, K., Schommers, P., Augustin, M., Crowell, C. S., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268530 · Cited by 36
Durstenfeld, M. S., Peluso, M. J., Kelly, J. D., Win, S., Swaminathan, S., Li, D., Arechiga, V. M., Zepeda, V., Sun, K., Shao, S. J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157053 · Cited by 35
Self-citationEvolution of functional antibodies following acute Epstein-Barr virus infection
Karsten, C. B., Bartsch, Y. C., Shin, S. A., Slein, M. D., Heller, H. M., Kolandaivelu, K., Middeldorp, J. M., Alter, G., & Jülg, B. D. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010738 · Cited by 29
The Use of Nirmatrelvir-ritonavir in a Case of Breakthrough Long COVID
Geng, L. N., Bonilla, H. F., Shafer, R. W., Miglis, M. G., & Yang, P. C.-M. (2023) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2022.00045 · Cited by 28
Sepúlveda, N., Malato, J., Sotzny, F., Grabowska, A. D., Fonseca, A., Cordeiro, C., Graça, L., Biecek, P., Behrends, U., Mautner, J., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.921101 · Cited by 23
Epstein-Barr virus and multiple sclerosis: supporting causality
Aloisi, F., & Salvetti, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00086-2 · Cited by 10
Cited by
Long COVID: major findings, mechanisms and recommendations
Davis, H. E., McCorkell, L., Vogel, J. M., & Topol, E. J. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00846-2 · Cited by 4,153
Distinguishing features of long COVID identified through immune profiling
Klein, J., Wood, J., Jaycox, J. R., Dhodapkar, R. M., Lu, P., Gehlhausen, J. R., Tabachnikova, A., Greene, K., Tabacof, L., Malik, A. A., et al. (2023) · Nature · doi:10.1038/s41586-023-06651-y · Cited by 806
Yin, K., Peluso, M. J., Luo, X., Thomas, R., Shin, M.-G., Neidleman, J., Andrew, A., Young, K. C., Ma, T., Hoh, R., et al. (2024) · Nature Immunology · doi:10.1038/s41590-023-01724-6 · Cited by 394
Self-citationAltmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J., & Boyton, R. J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00904-7 · Cited by 389
Mechanisms of long COVID and the path toward therapeutics
Peluso, M. J., & Deeks, S. G. (2024) · Cell · doi:10.1016/j.cell.2024.07.054 · Cited by 341
Self-citation
Metadata
- Authors
- Peluso, M. J., Deveau, T.-M., Munter, S. E., Ryder, D., Buck, A., Beck-Engeser, G., Chan, F., Lu, S., Goldberg, S. A., Hoh, R., Tai, V., Torres, L., Iyer, N. S., Deswal, M., Ngo, L. H., Buitrago, M., Rodriguez, A., Chen, J. Y., Yee, B. C., Chenna, A., Winslow, J. W., Petropoulos, C. J., Deitchman, A. N., Hellmuth, J., Spinelli, M. A., Durstenfeld, M. S., Hsue, P. Y., Kelly, J. D., Martin, J. N., Deeks, S. G., Hunt, P. W., & Henrich, T. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2023-02-01
- Volume
- 133
- Issue
- 3
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W4310494031
- Cited by
- 254
- References
- 52
- FWCI
- 25.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.